Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 4Sarcoma 3Genitourinary 2Thoracic 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2709Lung Neoplasms 2269Small Cell Lung Carcinoma 452Breast Neoplasms 394Neoplasms 348Colorectal Neoplasms 245Ovarian Neoplasms 208Pancreatic Neoplasms 196Melanoma 196Prostatic Neoplasms 187Adenocarcinoma of Lung 184Neoplasm Metastasis 177Head and Neck Neoplasms 175Mesothelioma, Malignant 152Esophageal Neoplasms 144Carcinoma, Renal Cell 142Stomach Neoplasms 141Colonic Neoplasms 138Urinary Bladder Neoplasms 124Mesothelioma 121Squamous Cell Carcinoma of Head and Neck 115Uterine Cervical Neoplasms 97Brain Neoplasms 87Sarcoma 86Kidney Neoplasms 82Carcinoma, Hepatocellular 71Liver Neoplasms 68Adenocarcinoma, Bronchiolo-Alveolar 68Rectal Neoplasms 64Pleural Effusion, Malignant 64

Interventions

Radiotherapy 1Paclitaxel 1Erlotinib Hydrochloride 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Clear Cell × Thoracic × Clear all
NCT00563784 2019-11-20

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

Phase 2 Completed
68 enrolled 11 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Adenocarcinoma, Clear Cell, Carcinoma, Giant Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡